ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last261 to 280 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Cases vs Controls: Prevalence of Melanoma Skin Cancer in Adult People Diagnosed With Vitiligo85 of 6,360

27 of 25,439

1.2 points

1.0 to 1.5

31,799NCT04969419

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Cases vs Controls: Prevalence of Actinic Keratoses in Adult People Diagnosed With Vitiligo111 of 6,360

363 of 25,439

0.3 points

-0.0 to 0.7

31,799NCT04969419

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Cases vs Controls: Prevalence of Skin Cancer in Adult People Diagnosed With Vitiligo66 of 6,360

293 of 25,439

-0.1 points

-0.4 to 0.2

31,799NCT04969419

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Cases vs Controls: Prevalence of Squamous Cell Carcinoma Skin Cancer in Adult People Diagnosed With Vitiligo13 of 6,360

72 of 25,439

-0.1 points

-0.2 to 0.1

31,799NCT04969419

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Cases vs Controls: Prevalence of Basal Cell Carcinoma Skin Cancer in Adult People Diagnosed With Vitiligo31 of 6,360

161 of 25,439

-0.1 points

-0.3 to 0.1

31,799NCT04969419

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Atorvastatin vs Simvastatin: Number of Participants With Post-index Cardiovascular (CV) Events700 of 11,470

1,012 of 20,132

1.1 points

0.6 to 1.6

31,602NCT01304641

Cardiovascular Events Based On Statin Initiation In The Elderly

Cases vs Controls (reference group): Risk of Anxiety Disorder Within Adult Patients With Vitiligo122 of 6,655

382 of 24,834

0.3 points

-0.0 to 0.7

31,489NCT04953338

Mental Health Associations With Vitiligo

Targeted Oral Azithromycin vs Targeted Oral Placebo: All-cause Mortality Rate in Individually Randomized Children at 4-12 Weeks of Age82 of 15,734

75 of 15,701

0.0 points

-0.1 to 0.2

31,435NCT03676764

Community Health Azithromycin Trial in Burkina Faso

Acute Ischemic Stroke (AIS) Patients Aged >80 Years Who Received IV Rt-PA (Alteplase) vs Acute Ischemic Stroke (AIS) Patients Aged 18 to 80 Years Who Received IV Rt-PA (Alteplase): Number of Patients With Stroke Recurrence During Hospitalization369 of 3,332

2,039 of 28,086

3.8 points

2.7 to 5.0

31,418NCT05395351

Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization

Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of Serostatus With Onset At Least 1 Day After the First Day 1 Vaccination115 of 15,708

259 of 15,592

-0.9 points

-1.2 to -0.7

31,300NCT04614948

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With Serious Adverse Events (SAEs)104 of 15,705

136 of 15,588

-0.2 points

-0.4 to -0.0

31,293NCT04614948

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With Medically-Attended Adverse Events (MAAEs)1,033 of 15,705

1,003 of 15,588

0.1 points

-0.4 to 0.7

31,293NCT04614948

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With Adverse Events of Special Interest (AESIs)2 of 15,705

1 of 15,588

0.0 points

-0.0 to 0.0

31,293NCT04614948

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double-Blind: Number of Participants With MAAEs Leading to Study Discontinuation4 of 15,705

8 of 15,588

-0.0 points

-0.1 to 0.0

31,293NCT04614948

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

People With Alopecia Areata vs People Without Alopecia Areata (Reference Gropup): Likelihood of Recurrent Major Depressive Disorder835 of 6,183

2,264 of 24,718

4.3 points

3.4 to 5.3

30,901NCT05727306

Healthcare Disparities in Alopecia Areata

People With Alopecia Areata vs People Without Alopecia Areata (Reference Group): Likelihood of Depressive Episodes1,217 of 6,183

3,576 of 24,718

5.2 points

4.1 to 6.3

30,901NCT05727306

Healthcare Disparities in Alopecia Areata

People With Alopecia Areata vs People Without Alopecia Areata (Reference Group): Likelihood of Anxiety Disorder1,113 of 6,183

3,188 of 24,718

5.1 points

4.1 to 6.2

30,901NCT05727306

Healthcare Disparities in Alopecia Areata

AZD1222 vs Placebo: Number of Participants With COVID-19 Severe or Critical Symptomatic Illness Post First Dose of Study Intervention5 of 20,589

16 of 10,300

-0.1 points

-0.2 to -0.1

30,889NCT04516746

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

AZD1222 vs Placebo: Number of Participants With COVID-19 Symptomatic Illness Post First Dose of Study Intervention287 of 20,589

303 of 10,300

-1.5 points

-1.9 to -1.2

30,889NCT04516746

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Anacetrapib vs Placebo Anacetrapib: Number of Participants With Major Coronary Event1,640 of 15,225

1,803 of 15,224

-1.1 points

-1.8 to -0.4

30,449NCT01252953

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=14

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04969419-058d8e05",
        "title": "Cases vs Controls: Prevalence of Melanoma Skin Cancer in Adult People Diagnosed With Vitiligo",
        "summary": "85 of 6360 against 27 of 25439; risk difference 1.2 points, 95% interval 1.0 to 1.5; NCT04969419, Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo",
        "record": "/library/comparisons/NCT04969419-058d8e05",
        "nct_id": "NCT04969419",
        "kind": "outcome",
        "participants": 31799,
        "risk_difference": {
          "value": 0.012303417399273785,
          "lower": 0.009715262855959066,
          "upper": 0.015451245198251876
        },
        "group_1": "85 of 6,360",
        "group_2": "27 of 25,439",
        "difference": "1.2 points",
        "interval": "1.0 to 1.5",
        "trial_title": "Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo"
      },
      {
        "id": "NCT04969419-20b7519f",
        "title": "Cases vs Controls: Prevalence of Actinic Keratoses in Adult People Diagnosed With Vitiligo",
        "summary": "111 of 6360 against 363 of 25439; risk difference 0.3 points, 95% interval -0.0 to 0.7; NCT04969419, Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo",
        "record": "/library/comparisons/NCT04969419-20b7519f",
        "nct_id": "NCT04969419",
        "kind": "outcome",
        "participants": 31799,
        "risk_difference": {
          "value": 0.003183401358929647,
          "lower": -0.00013134124876132457,
          "upper": 0.006968036039955014
        },
        "group_1": "111 of 6,360",
        "group_2": "363 of 25,439",
        "difference": "0.3 points",
        "interval": "-0.0 to 0.7",
        "trial_title": "Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=15",
  "request_id": "x9i0-_2JE79Bj92R"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?